share_log

Credit Suisse Initiates Coverage On Blueprint Medicines with Neutral Rating, Announces Price Target of $100

Credit Suisse Initiates Coverage On Blueprint Medicines with Neutral Rating, Announces Price Target of $100

瑞士信贷(Credit Suisse)启动中性评级的蓝图药物覆盖范围,宣布目标价为100美元
Benzinga Real-time News ·  2021/03/31 19:13

Credit Suisse analyst Brad Canino initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Neutral rating and announces Price Target of $100.

瑞士信贷(Credit Suisse)分析师布拉德·卡尼诺(Brad Canino)开始报道Blueprint Medicines(纳斯达克:BPMC)评级为中性,并宣布目标价为100美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发